CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,320,375 | $4,959,230 | $3,160,398 | $5,755,391 |
| - Cash | $298,257 | $389,477 | $211,885 | $923,031 |
| + Debt | $223,693 | $238,632 | $244,021 | $225,030 |
| Enterprise Value | $3,245,811 | $4,808,385 | $3,192,534 | $5,057,390 |
| Revenue | $35,000 | $370,000 | $436 | $913,081 |
| % Growth | -90.5% | 84,762.4% | -100% | – |
| Gross Profit | -$75,250 | $239,750 | -$109,814 | $811,903 |
| % Margin | -215% | 64.8% | -25,186.7% | 88.9% |
| EBITDA | -$447,307 | -$202,701 | -$648,989 | $391,481 |
| % Margin | -1,278% | -54.8% | -148,850.7% | 42.9% |
| Net Income | -$366,252 | -$153,610 | -$650,175 | $377,661 |
| % Margin | -1,046.4% | -41.5% | -149,122.7% | 41.4% |
| EPS Diluted | -4.34 | -1.94 | -8.36 | 4.7 |
| % Growth | -123.7% | 76.8% | -277.9% | – |
| Operating Cash Flow | -$142,774 | -$260,375 | -$495,741 | $538,972 |
| Capital Expenditures | -$1,901 | -$9,470 | -$37,188 | -$81,705 |
| Free Cash Flow | -$144,675 | -$269,845 | -$532,929 | $457,267 |